|
|
Article: Genmab to Present HuMax-CD4 Data at the Society for Investigative Dermatology Conference; 67% of Early Stage and 50% of Advanced Stage Patients Obtained CA Score Reduction of at Least 50% in High Dose Group.
- Article from:
- PR Newswire
- Article date:
- February 18, 2004
CopyrightCOPYRIGHT 2004 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Genmab A/S announced today it will present data from Phase II HuMax-CD4 studies to treat cutaneous T-cell lymphoma (CTCL) at the 65th Annual Meeting of the Society for Investigative Dermatology in April. At the time the abstract was completed, 36 patients enrolled in the two ongoing HuMax-CD4 clinical trials were evaluated using the Composite Assessment of Index Lesion Disease Activity (CA) score. These patients were treated at one of three dose levels as follows: 280 mg (11 early stage and 10 advanced stage), 560 mg (9 early stage) or 980 mg (6 advanced stage).
Following 280 mg, 33% of 21 patients obtained a 50% or better CA score reduction. Following 560 ...